Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 32

1.

Unsaturated fatty acids regulate stemness of ovarian cancer cells through NF-κB.

Parrales A, Ranjan A, Iwakuma T.

Stem Cell Investig. 2017 Jun 3;4:49. doi: 10.21037/sci.2017.05.07. eCollection 2017. No abstract available.

2.

Ovarian cancer stem cells: still an elusive entity?

Lupia M, Cavallaro U.

Mol Cancer. 2017 Mar 20;16(1):64. doi: 10.1186/s12943-017-0638-3. Review.

3.

B7-H4 expression in ovarian serous carcinoma: a study of 306 cases.

Liang L, Jiang Y, Chen JS, Niu N, Piao J, Ning J, Zu Y, Zhang J, Liu J.

Hum Pathol. 2016 Nov;57:1-6. doi: 10.1016/j.humpath.2016.06.011. Epub 2016 Jun 24.

PMID:
27349304
4.

Prognostic value of the expression of cancer stem cell-related markers CD133 and CD44 in hepatocellular carcinoma: From patients to patient-derived tumor xenograft models.

Zhao Q, Zhou H, Liu Q, Cao Y, Wang G, Hu A, Ruan L, Wang S, Bo Q, Chen W, Hu C, Xu D, Tao F, Cao J, Ge Y, Yu Z, Li L, Wang H.

Oncotarget. 2016 Jul 26;7(30):47431-47443. doi: 10.18632/oncotarget.10164.

5.

Targeting epithelial-mesenchymal transition and cancer stem cells for chemoresistant ovarian cancer.

Deng J, Wang L, Chen H, Hao J, Ni J, Chang L, Duan W, Graham P, Li Y.

Oncotarget. 2016 Aug 23;7(34):55771-55788. doi: 10.18632/oncotarget.9908. Review.

6.

Biological markers of prognosis, response to therapy and outcome in ovarian carcinoma.

Szajnik M, Czystowska-Kuźmicz M, Elishaev E, Whiteside TL.

Expert Rev Mol Diagn. 2016 Aug;16(8):811-26. doi: 10.1080/14737159.2016.1194758. Epub 2016 Jun 23.

7.

Stemness and chemoresistance in epithelial ovarian carcinoma cells under shear stress.

Ip CK, Li SS, Tang MY, Sy SK, Ren Y, Shum HC, Wong AS.

Sci Rep. 2016 Jun 1;6:26788. doi: 10.1038/srep26788.

8.

A chemotherapy response classifier based on support vector machines for high-grade serous ovarian carcinoma.

Sun CY, Su TF, Li N, Zhou B, Guo ES, Yang ZY, Liao J, Ding D, Xu Q, Lu H, Meng L, Wang SX, Zhou JF, Xing H, Weng DH, Ma D, Chen G.

Oncotarget. 2016 Jan 19;7(3):3245-54. doi: 10.18632/oncotarget.6569.

9.

Prognostic value of cancer stem cell marker CD133 in ovarian cancer: a meta-analysis.

Zhou Q, Chen A, Song H, Tao J, Yang H, Zuo M.

Int J Clin Exp Med. 2015 Mar 15;8(3):3080-8. eCollection 2015. Review.

10.

Identification of a distinct population of CD133(+)CXCR4(+) cancer stem cells in ovarian cancer.

Cioffi M, D'Alterio C, Camerlingo R, Tirino V, Consales C, Riccio A, Ieranò C, Cecere SC, Losito NS, Greggi S, Pignata S, Pirozzi G, Scala S.

Sci Rep. 2015 May 28;5:10357. doi: 10.1038/srep10357.

11.

Molecular staging of gynecological cancer: What is the future?

Binder PS, Prat J, Mutch DG.

Best Pract Res Clin Obstet Gynaecol. 2015 Aug;29(6):776-89. doi: 10.1016/j.bpobgyn.2015.01.008. Epub 2015 Mar 4. Review.

12.

Elafin is downregulated during breast and ovarian tumorigenesis but its residual expression predicts recurrence.

Caruso JA, Karakas C, Zhang J, Yi M, Albarracin C, Sahin A, Bondy M, Liu J, Hunt KK, Keyomarsi K.

Breast Cancer Res. 2014;16(6):3417. Erratum in: Breast Cancer Res. 2015;17:87.

13.

Developing ovarian cancer stem cell models: laying the pipeline from discovery to clinical intervention.

Ffrench B, Gasch C, O'Leary JJ, Gallagher MF.

Mol Cancer. 2014 Dec 11;13:262. doi: 10.1186/1476-4598-13-262. Review.

14.

Platinum sensitivity and CD133 expression as risk and prognostic predictors of central nervous system metastases in patients with epithelial ovarian cancer.

Liu BL, Liu SJ, Baskys A, Cheng H, Han Y, Xie C, Song H, Li J, Xin XY.

BMC Cancer. 2014 Nov 17;14:829. doi: 10.1186/1471-2407-14-829.

15.

Ovarian cancer stem cells: Can targeted therapy lead to improved progression-free survival?

Walters Haygood CL, Arend RC, Straughn JM, Buchsbaum DJ.

World J Stem Cells. 2014 Sep 26;6(4):441-7. doi: 10.4252/wjsc.v6.i4.441. Review.

16.

Investigating molecular profiles of ovarian cancer: an update on cancer stem cells.

Tomao F, Papa A, Strudel M, Rossi L, Lo Russo G, Benedetti Panici P, Ciabatta FR, Tomao S.

J Cancer. 2014 Mar 16;5(5):301-10. doi: 10.7150/jca.8610. eCollection 2014. Review.

17.

Cancer stem cell markers correlate with early recurrence and survival in hepatocellular carcinoma.

Guo Z, Li LQ, Jiang JH, Ou C, Zeng LX, Xiang BD.

World J Gastroenterol. 2014 Feb 28;20(8):2098-106. doi: 10.3748/wjg.v20.i8.2098.

18.

Ovarian cancer stem cells: are they real and why are they important?

Shah MM, Landen CN.

Gynecol Oncol. 2014 Feb;132(2):483-9. doi: 10.1016/j.ygyno.2013.12.001. Epub 2013 Dec 7. Review.

19.

Hypomethylation signature of tumor-initiating cells predicts poor prognosis of ovarian cancer patients.

Liao YP, Chen LY, Huang RL, Su PH, Chan MW, Chang CC, Yu MH, Wang PH, Yen MS, Nephew KP, Lai HC.

Hum Mol Genet. 2014 Apr 1;23(7):1894-906. doi: 10.1093/hmg/ddt583. Epub 2013 Nov 20.

20.

miR-106a represses the Rb tumor suppressor p130 to regulate cellular proliferation and differentiation in high-grade serous ovarian carcinoma.

Liu Z, Gersbach E, Zhang X, Xu X, Dong R, Lee P, Liu J, Kong B, Shao C, Wei JJ.

Mol Cancer Res. 2013 Nov;11(11):1314-25. doi: 10.1158/1541-7786.MCR-13-0131. Epub 2013 Sep 17.

Supplemental Content

Support Center